Patient Dies Following Gene Therapy Treatment for Duchenne Muscular Dystrophy

A patient suffered acute liver failure after Elevidys treatment, with Sarepta Therapeutics citing a preexisting infection as a possible contributing factor.

A mobile phone with the logo of Sarepta Therapeutics on screen in front of a web page in Stuttgart, Germany, on July 16, 2022. Shutterstock

A patient with Duchenne muscular dystrophy has died following treatment with Elevidys, a gene therapy developed by Sarepta Therapeutics, the company announced in a safety update. The news sent the company’s stock down about 23 percent in morning trading on March 18.

“We are profoundly saddened to share that a young man with Duchenne muscular dystrophy has passed away following treatment with ELEVIDYS, having suffered acute liver failure,” a company report read.